The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
Open accessAbstract
The central problem in cancer chemotherapy is the severe toxic side effects of anticancer drugs on healthy tissues. Invariably the side effects impose dose reduction, treatment delay, or discontinuance of therapy. To limit the adverse side effects of cancer chemotherapy on healthy organs, we proposed a drug delivery system (DDS) with specific targeting ligands for cancer cells. The proposed DDS minimizes the uptake of the drug by normal cells and enhances the influx and retention of the drug in cancer cells. This delivery system includes three main components: ( i ) an apoptosis-inducing agent (anticancer drug), ( ii ) a targeting moiety-penetration enhancer, and ( iii ) a carrier. We describe one of the variants of such a system, which utilizes camptothecin as an apoptosis-inducing agent and poly(ethylene glycol) as a carrier. Luteinizing hormone-releasing hormone (LHRH) was used as a targeting moiety (ligand) to LHRH receptors that are overexpressed in the plasma membrane of several types of cancer cells and are not expressed detectably in normal visceral organs. The results showed that the use of LHRH peptide as a targeting moiety in the anticancer DDS substantially enhanced the efficacy of chemotherapy, led to amplified apoptosis induction in the tumor, and minimized the side effects of the anticancer drug on healthy organs. The LHRH receptor targeting DDS did not show in vivo pituitary toxicity and did not significantly influence the time course or the plasma concentration of luteinizing hormone and its physiological effects on the reproductive functions of mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polysaccharides in colon-specific drug delivery
Sinha, V. R., & Kumria, R. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00720-7 · Cited by 872
Welt, F. G. P., & Edelman, E. R. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)90003-x · Cited by 863
Greenwald, R. B. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00331-5 · Cited by 353
Folate receptor-targeted drugs for cancer and inflammatory diseases
Low, P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.003 · Cited by 306
Lukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R., & Torchilin, V. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.007 · Cited by 294
Drug targeting to the colon with lectins and neoglycoconjugates
Minko, T. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.017 · Cited by 222
Self-citationFang, J., Sawa, T., & Maeda, H. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-47932-x_2 · Cited by 221
Endogenous lectins as targets for drug delivery
Yamazaki, N., Kojima, S., Bovin, N. V., André, S., Gabius, S., & Gabius, H.-J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00071-5 · Cited by 200
Minko, T., Kope?kov�, P., & Kope?ek, J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<108::aid-ijc17>3.0.co;2-8 · Cited by 198
Self-citationFolate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma
Turk, M. J., Waters, D. J., & Low, P. S. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.12.028 · Cited by 196
Molecular Targeting of Drug Delivery Systems to Cancer
Minko, T., Dharap, S., Pakunlu, R., & Wang, Y. (2004) · Current Drug Targets · doi:10.2174/1389450043345443 · Cited by 175
Self-citationMolecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
Dharap, S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00209-8 · Cited by 172
Self-citationGrundker, C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1427 · Cited by 168
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
ROSS, R. W., & SMALL, E. J. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65060-4 · Cited by 161
Pakunlu, R. I., Wang, Y., Tsao, W., Pozharov, V. P., Cook, T. J., & Minko, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0001 · Cited by 148
Self-citationOsteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Ross, R. W., & Small, E. J. (2002) · The Journal of Urology · doi:10.1097/00005392-200205000-00003 · Cited by 142
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
Trail, P. A., King, D. H., & Dubowchik, G. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0352-9 · Cited by 140
EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer
Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C. W., Chui, C. H., Franz, G., Senter, P. D., Koeppen, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1047 · Cited by 127
Völker, P., Gründker, C., Schmidt, O., Schulz, K.-D., & Emons, G. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.119633 · Cited by 125
Lectin-mediated transport of nanoparticles across Caco-2 and OK cells
Russell-Jones, G. J., Veitch, H. S., & Arthur, L. M. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00254-9 · Cited by 116
Polymerizable Fab′ antibody fragments for targeting of anticancer drugs
Lu, Z., Kopečková, P., & Kopeček, J. (1999) · Nature Biotechnology · doi:10.1038/15085 · Cited by 113
David, A., Kopečková, P., Minko, T., Rubinstein, A., & Kopec̆ek, J. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.07.001 · Cited by 113
Self-citationCircadian chemotherapy for gynecological and genitourinary cancers
Kobayashi, M., Wood, P. A., & Hrushesky, W. J. M. (2002) · Chronobiology International · doi:10.1081/cbi-120002600 · Cited by 109
Selected Contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal α-tocopherol
Minko, T., Stefanov, A., & Pozharov, V. P. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00007.2002 · Cited by 64
Self-citationMinko, T., Kopečková, P., Pozharov, V., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007500412442 · Cited by 62
Self-citationLectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro
Wirth, M., Gerhardt, K., Wurm, C., & Gabor, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00538-7 · Cited by 55
Folate Receptor-Mediated Targeting of Liposomal Drugs to Cancer Cells
Stephenson, S. M., Low, P. S., & Lee, R. J. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)87003-4 · Cited by 50
Cited by
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Polymer–drug conjugates: Progress in polymeric prodrugs
Khandare, J., & Minko, T. (2006) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2005.09.004 · Cited by 639
Self-citationShen, Y., Jin, E., Zhang, B., Murphy, C. J., Sui, M., Zhao, J., Wang, J., Tang, J., Fan, M., Van Kirk, E., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909475m · Cited by 565
Tao, K., Levin, A., Adler-Abramovich, L., & Gazit, E. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00889a · Cited by 482
Metadata
- Authors
- Dharap, S. S., Wang, Y., Chandna, P., Khandare, J. J., Qiu, B., Gunaseelan, S., Sinko, P. J., Stein, S., Farmanfarmaian, A., & Minko, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-08-25
- Volume
- 102
- Issue
- 36
- Pages
- 12962-12967
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1988754095
- Cited by
- 340
- References
- 27
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.